UNSPSC 51352102: Taleranol

This classification denotes a non-steroidal estrogen with the molecular formula C18H26O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HUN219N434, chemically known as 2,4-dihydroxy-6-(6beta,10-dihydroxyundecyl]benzoic acid mu-lactone but generally known as taleranol, which bears US NIH Compound Identifier 65434. European Medicines Agency schedules Taleranol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10803MIG.

UNSPSC 51352102 Taleranol is a Commodity code covering pharmaceutical products supplied through state and local cooperative purchasing vehicles. State and local governments procure generic multi-source pharmaceuticals and over-the-counter products under this code through authorized wholesalers to supply public health facilities, hospitals, correctional institutions, and other state and local agencies. The work involves manufacturers supplying products with specific National Drug Codes (NDC), detailed product information including strength, dosage form, packaging configurations, and manufacturing locations, compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), and maintenance of contractual relationships with authorized wholesalers equipped with chargeback systems. Pricing structures vary—vendors may offer flat price, net price formats (NF30, NF60, NF90), or WAC-minus pricing—and vendors must maintain comprehensive insurance including commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000. Issuing bodies include state health and human services departments, departments of administration, and multistate cooperative purchasing alliances that aggregate demand across multiple participating states and local jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, with a proposal due date of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities including Oregon. The evaluation emphasizes price competitiveness (75 percent weight), with secondary criteria including fixed pricing for contract term (10 percent), price format compliance (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). All products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026. The contract term is two years for new responders with optional extensions at MMCAP's sole discretion, while incumbent responders' amendments align with existing agreement expiration dates through June 30, 2028. Vendors are required to pay a 3 percent administrative fee on all contract purchases and comply with performance penalties ranging from $200 to $1,500 per violation.